Use Of Probiotics In Management Research Articles

Use of Probiotics for Management and Intervention of Cardiovascular Diseases in Humans

Use of Probiotics for Management and Intervention of Cardiovascular Diseases in Humans

The Use of Probiotics for Management and Improvement of Reproductive Eubiosis and Function.

Reproductive tract dysbiosis, due to the action of pathogens and/or unhealthy lifestyle, has been related to many reproductive diseases and disorders in mammalian species. Classically, such a problem has been confronted by the administration of antibiotics. Despite their effectiveness for controlling disease, treatments with antibiotics may negatively affect the fertility of males and females and, mainly, may induce antibiotic resistance. Accordingly, safer alternatives for maintaining reproductive system eubiosis, such as probiotics, are required. The present review summarizes the current knowledge on the biodiversity of the microbiota at the reproductive tract, possible changes in the case of dysbiosis, and their relationships with adequate reproductive health and functioning in both females and males. Afterwards, mechanisms of action and benefits of different probiotics are weighed since the biological activities of probiotics may provide a promising alternative to antibiotics for maintaining and restoring reproductive eubiosis and function. However, at present, it is still necessary for further research to focus on: (a) identifying mechanisms by which probiotics can affect reproductive processes; (b) the safety of probiotics to the host, specifically when consumed during sensitive reproductive windows such as pregnancy; and (c) the hazards instructions and regulatory rules required for marketing these biological-based therapies with sufficient safety. Thus, in this review, to draw a comprehensive overview with a relatively low number of clinical studies in this field, we showed the findings of studies performed either on human or animal models. This review strategy may help provide concrete facts on the eligible probiotic strains, probiotics colonization and transfer route, and prophylactic and/or therapeutic effects of different probiotic strains.

Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials.

Patients with cystic fibrosis (CF) usually have abnormal intestinal microbiota due to massive exposure to antibiotics. Probiotics could modify the gut microbiota and hence may affect CF management. So the aim of present systematic review was evaluation of the efficacy and safety of probiotic supplementation for the management of cystic fibrosis. We searched PubMed, Science Direct, Google Scholar, Springer Cochrane Library Databases until January 2016 for randomized controlled trials (RCTs) performed in pediatric or adult populations related to the study aim. Key words were selected based on Mesh terms. Based on the Critical Appraisal Skills Programme checklist, eligibility of included articles was evaluated. Five studies included in this review represent 188 participants with a follow up period ranging from 1 month to 6 months. The results of the included studies supporting the use of probiotics in management of pulmonary exacerbation and intestinal calprotectin in patients with cystic fibrosis. However the level of evidence was limited. The lack of high quality RCTs makes it impossible to support a general recommendation about the use of probiotics in the treatment of CF pulmonary exacerbation and intestinal inflammation.

Use of Probiotics for Management of Acute Gastroenteritis

Use of Probiotics for Management of Acute Gastroenteritis

Use of Probiotics for Management of Acute Gastroenteritis

The use of probiotics has been suggested in the treatment of acute gastroenteritis (AGE) in addition to early rehydration and avoidance of dietary restrictions. This document provides recommendations for the use of probiotics for the treatment of AGE in previously healthy infants and children based on a systematic review of previously completed systematic reviews and of randomized controlled trials (RCTs) published subsequently to these reviews. The recommendations were formulated only if at least 2 RCTs that used a given probiotic (with strain specification) were available. The GRADE system developed by the Grading of Recommendations, Assessment, Development, and Evaluations Working Group, was used to grade the strength of evidence and grades of recommendations used in these guidelines. It offers 4 categories of the quality of the evidence (high, moderate, low, and very low) and 2 categories of the strength of recommendation (strong or weak). The use of the following probiotics (in alphabetical order) may be considered in the management of children with AGE in addition to rehydration therapy: Lactobacillus rhamnosus GG (low quality of evidence, strong recommendation) and Saccharomyces boulardii (low quality of evidence, strong recommendation). Less compelling evidence is available for Lactobacillus reuteri DSM 17938 (very low quality of evidence, weak recommendation) and heat-inactivated Lactobacillus acidophilus LB (very low quality of evidence, weak recommendation). The latter, although traditionally discussed with other probiotics, does not fit with the definition of probiotics. Other strains or combinations of strains have been tested, but evidence of their efficacy is weak or preliminary.

Clinical potential for the use of probiotics in the management of respiratory conditions and cold- and influenza-like symptoms

Clinical potential for the use of probiotics in the management of respiratory conditions and cold- and influenza-like symptoms Matthias Volkmar Kopp1, Tobias Ankermann2, Christoph Härtel11Klinik für Kinder und Jugendmedizin University Lübeck, Lübeck, Germany; 2Klinik für Allgemeine Pädiatrie, Christian-Albrechts-University Kiel, GermanyAbstract: Respiratory conditions including complaints like cough, rhinitis, sinusitis, or influenza-like symptoms are commonly summarized as acute upper respiratory tract infections (URTIs). The mechanisms of the potential beneficial effects of probiotics in the management of URTIs are not completely elucidated. Possible explanations are any or all of the following: 1) probiotics compete against other pathogens for colonization of the upper respiratory tract, 2) probiotics increase the barrier function, and 3) probiotics directly cause immunomodulatory effects. Here we review the current evidence for the use of probiotics in the clinical management of URTIs in different age groups. Animal studies and in vitro data reveal that probiotics might have clinical potential in the management of URTIs. In contrast, data from double-blind placebo-controlled clinical trials show conflicting results. Given the current level of evidence, it is therefore not appropriate to recommend probiotics as a part of standard therapy or for the management of URTIs.Keywords: probiotics, prevention, infection, respiratory tract, asthma, children